Discovery of a Novel CSF-1R Inhibitor with Highly Improved Pharmacokinetic Profiles and Superior Efficacy in Colorectal Cancer Immunotherapy
Journal of Medicinal Chemistry · 25.04.2024 · 67 (8) · 6854-6879
DOI: 10.1021/acs.jmedchem.4c00508 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 09.04.2024. Verfasst von Qi Lv und 10 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, P. R…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Immunotherapy, Receptor, Macrophage Colony-Stimulating Factor. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Graduate Research and Innovation Projects of Jiangsu Province, Natural Science Foundation of Jiangsu Province, Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions.
Abstract (Originalsprache)
Blocking CSF-1/CSF-1R pathway has emerged as a promising strategy to remodel tumor immune microenvironment (TME) by reprogramming tumor-associated macrophages (TAMs). In this work, a novel CSF-1R inhibitor C19 with a highly improved pharmacokinetic profile and in vivo anticolorectal cancer (CRC) efficiency was successfully discovered. C19 could effectively reprogram M2-like TAMs to M1 phenotype and reshape the TME by inducing the recruitment of CD8+ T cells into tumors and reducing the infiltration of immunosuppressive Tregs/MDSCs. Deeper mechanistic studies revealed that C19 facilitated the infiltration of CD8+ T cells by enhancing the secretion of chemokine CXCL9, thus significantly potentiating the anti-CRC efficiency of PD-1 blockade. More importantly, C19 combined with PD-1 mAb could induce durable antitumor immune memory, effectively overcoming the recurrence of CRC. Taken together, our findings suggest that C19 is a promising therapeutic option for sensitizing CRC to anti-PD-1 therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, P. R. China.
- Jiangsu Provincial Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, P. R. China.
ORCID-Profile: Junwei Wang
Förderung
- Graduate Research and Innovation Projects of Jiangsu Province
- Natural Science Foundation of Jiangsu Province
- Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions
- National Natural Science Foundation of China
Zitieren
APA
Lv, Q., Yang, H., Wang, D., Zhou, H., Wang, J., Zhang, Y., Wu, D., Xie, Y., Lv, Y., Hu, L., & Wang, J. (2024). Discovery of a Novel CSF-1R Inhibitor with Highly Improved Pharmacokinetic Profiles and Superior Efficacy in Colorectal Cancer Immunotherapy. Journal of Medicinal Chemistry, 67(8), 6854-6879. https://doi.org/10.1021/acs.jmedchem.4c00508
Vancouver
Lv Q, Yang H, Wang D, Zhou H, Wang J, Zhang Y, et al. Discovery of a Novel CSF-1R Inhibitor with Highly Improved Pharmacokinetic Profiles and Superior Efficacy in Colorectal Cancer Immunotherapy. Journal of Medicinal Chemistry. 2024;67(8):6854-6879. doi:10.1021/acs.jmedchem.4c00508
BibTeX
@article{Lv2024,
author = {Lv, Qi and Yang, Hongqiong and Wang, Dan and Zhou, Haikun and Wang, Juan and Zhang, Yishu and Wu, Dapeng and Xie, Ying and Lv, Yingshan and Hu, Lihong and Wang, Junwei},
title = {Discovery of a Novel CSF-1R Inhibitor with Highly Improved Pharmacokinetic Profiles and Superior Efficacy in Colorectal Cancer Immunotherapy},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {8},
pages = {6854--6879},
doi = {10.1021/acs.jmedchem.4c00508}
}
EUVIMED